ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Chad Gassert Sells 20,000 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Free Report) SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $67.25, for a total value of $1,345,000.00. Following the sale, the senior vice president now owns 253,226 shares of the company’s stock, valued at $17,029,448.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

ANI Pharmaceuticals Trading Down 1.7 %

Shares of ANIP traded down $1.15 during trading hours on Tuesday, hitting $66.72. 173,569 shares of the stock were exchanged, compared to its average volume of 137,700. ANI Pharmaceuticals, Inc. has a fifty-two week low of $36.99 and a fifty-two week high of $70.81. The business has a 50-day moving average of $62.06 and a 200-day moving average of $57.94. The firm has a market capitalization of $1.41 billion, a P/E ratio of 79.43 and a beta of 0.79. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.57 and a quick ratio of 2.81.

ANI Pharmaceuticals (NASDAQ:ANIPGet Free Report) last issued its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ANIP. Guggenheim upped their target price on ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Truist Financial upped their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 1st. HC Wainwright lifted their price target on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Finally, Capital One Financial initiated coverage on ANI Pharmaceuticals in a research report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $80.00.

View Our Latest Analysis on ANIP

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. BlackRock Inc. raised its position in shares of ANI Pharmaceuticals by 9.9% during the second quarter. BlackRock Inc. now owns 2,133,100 shares of the specialty pharmaceutical company’s stock worth $114,825,000 after purchasing an additional 191,402 shares during the period. Vanguard Group Inc. increased its stake in ANI Pharmaceuticals by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 1,288,972 shares of the specialty pharmaceutical company’s stock valued at $71,074,000 after purchasing an additional 156,594 shares in the last quarter. Rubric Capital Management LP raised its holdings in ANI Pharmaceuticals by 32.8% during the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock worth $62,032,000 after buying an additional 277,989 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of ANI Pharmaceuticals by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock valued at $32,628,000 after buying an additional 33,359 shares in the last quarter. Finally, Global Alpha Capital Management Ltd. grew its holdings in shares of ANI Pharmaceuticals by 10.8% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock valued at $32,115,000 after buying an additional 56,900 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Further Reading

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.